Circulating Long and Circular Noncoding RNA as Non-Invasive Diagnostic Tools of Hepatocellular Carcinoma

Caecilia H. C. Sukowati 1,†, Loraine Kay D. Cabral 1,2, Claudio Tiribelli 1 and Devis Pascut 1,*†

1 Fondazione Italiana Fegato ONLUS, AREA Science Park, Campus Basovizza, SS14, km 163.5, 34149 Trieste, Italy; caecilia.sukowati@fegato.it (C.H.C.S.); kay.cabral@fegato.it (L.K.D.C.); ctliver@fegato.it (C.T.)
2 Doctoral School in Molecular Biomedicine, University of Trieste, 34100 Trieste, Italy
* Correspondence: devis.pascut@fegato.it; Tel.: +39-040-3757925
† These authors contributed equally to the publication.

Abstract: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related death worldwide, partially due to late diagnosis of the disease. Growing evidence in the field of biomarker discovery has shown the promising use of nucleic acid in the early detection of many cancers, including HCC. Here, we review data on how various long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) could be used as a diagnostic tool for HCC being differentially expressed in HCC compared to non-HCC patients. These non-coding RNAs (ncRNAs) showed high stability in the blood being present as free-circulating molecules or encapsulated into exosomes. This review reports some recent evidence on the use of lncRNAs and circRNAs as possible diagnostic biomarkers for HCC. Further, their pathophysiological mechanism in liver carcinogenesis was also described, elucidating the complex regulatory networks making these ncRNAs of particular relevance for the study of liver malignancy cancer.

Keywords: hepatocellular carcinoma; ncRNAs; lncRNA; circRNA; non-invasive biomarker; diagnosis

1. Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, ranking as the sixth most common malignancy and the fourth most common cancer-related death, for both sexes [1,2]. The incidence and the mortality rates are comparable (840,000 and 780,000 per year, respectively, GLOBOCAN 2018), pointing to a high mortality risk for the disease.

HCC is a heterogeneous malignancy, often occurring in a setting of cirrhosis caused by multiple etiological factors. Major risk factors for HCC are chronic infection of hepatitis B virus (HBV) and/or hepatitis C virus (HCV), alcoholic liver disease, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH), and exposure to aflatoxin. Even though active hepatitis C and B chronic infection continue to drive most of the global burden of HCC, the booming rising of the metabolic syndrome manifested to NASH is a major cause of liver disease that may lead to the development of HCC [3,4]. Overall, one-third of cirrhotic patients will develop HCC [5].

The management of HCC is based on a standard protocol on the surveillance, diagnosis, and treatment recommendation of international guidelines [6–8]. The European guideline (Barcelona Clinic Liver Cancer/BCLC) strongly recommends non-invasive criteria for HCC diagnosis in a cirrhotic setting, while the diagnosis must be confirmed by pathology in non-cirrhotic livers [6]. For the very early stage HCC (BCLC 0) and early-stage (BCLC A), curative treatment such as liver resection, liver transplantation, and ablation [4] are recommended since they result in a five-year survival higher than 50% [9]. For the intermediate stage (BCLC B), transarterial chemoembolization (TACE) was considered the first-line treatment, with a median survival of around 40 months in well-selected
candidates, with a state-of-the-art technique and a super-selective approach based on the strict evaluation of tumor characteristics including tumor number, size, and liver function. Patients in an advanced stage can receive systemic therapies, Sorafenib as a first-line drug [10], while patients in the terminal stage can only receive best supportive care with median survival of three to four months or 11% at one year [11]. Early diagnosis of HCC is fundamental for the improved survival of the patients, summarized in [6].

In cancer research, including in HCC, noninvasive liquid biopsy has become an attractive modality for the early detection of cancer. Liquid biopsy is a method where biomarkers in bodily fluid samples are used to determine the pathophysiological state of an individual. It is commonly used for the diagnosis, prognosis, monitoring, and treatment choice of a disease.

Serum alpha-fetoprotein (AFP) is still the most common serum biomarker for HCC screening and diagnosis. However, the use of AFP alone is limited since not all HCC cells that secrete AFP and AFP may be elevated in cirrhosis or hepatitis [12]. A multicenter study with more than 1100 HCC subjects showed a low sensitivity (54%) of AFP in the diagnosis of HCC and a prognostic value area under the curve (AUC) of 0.59 [13]. A previous systematic review reported that, using a cut-off of 20 ng/mL, AFP showed a specificity of 80–92%, but a poor sensitivity of 41–65% [14].

Cancer by-products, including circulating tumor cells (CTCs), cell-free nucleic acids (cfDNA and cfRNA), extracellular vesicles (EVs), and tumor-derived metabolites, are common biomarkers used to detect the presence of malignancy. Both cfDNA and cfRNA are released into the circulation via various systems, including active secretion or means of the apoptosis, necrosis, and lysis of CTCs [15]. The presence of these molecules in the fluid (usually in peripheral blood) can be used to represent the cancer tissue of origin. Together with its non-invasive approach, cfRNA biomarkers are more dynamically regulated, tissue-specific, and abundant in extracellular environments [16].

Many studies reported the significance and diagnostic power of microRNAs (miRNAs) biomarkers for HCC diagnosis. However, little is known about the presence of long cfRNA in circulation. This review presents available information on long cfRNAs, in particular the long non-coding RNA (lncRNA) and circular-RNA (circRNA) for early diagnosis of HCC.

2. Non-Coding RNAs

In the beginning, cancer studies were mainly based on the central dogma of biology focusing on protein-coding genes. In the last decades; however, discoveries of novel structural and functional nucleic acids open up new knowledge in biology and medicine. Advances in high-throughput nucleic acid technologies facilitates a systematic screening and possible discovery of various new molecules. The human genome is pervasively transcribed and produces thousands of regulatory non-protein-coding RNAs (ncRNAs), including microRNAs (miRNAs), small interfering RNAs (siRNAs), PIWI-interacting RNAs (piRNAs), circular RNA (circRNA), and various classes of long ncRNAs [17]. These ncRNAs were plastic and they are capable of complex mechanisms in a broad- and sequence-specific manner [17].

2.1. Free-Circulating lncRNAs

The study from Iyer et al. (2015) showed that, from a consensus of around 91,000 human genes, over 68% of genes were classified as long noncoding RNAs (lncRNAs), of which 79% were previously unannotated [18]. The lncRNAs, non-protein-coding transcripts with length > 200 nucleotides (nt), is the broadest class in non-coding RNA, including mRNA-like ncRNAs [17]. It is involved in multiple mechanisms in an organism. Accumulating evidence showed that these functional RNA molecules were important regulatory molecules in many, if not all, biological processes across organisms [19]. Multiple functions of this RNA included the recruitment of chromatin-modifying enzymes or interaction with proteins to direct their binding to DNA, also in epigenetic regulation of protein-coding gene expression [19,20].
LncRNAs contribute to the pathogenesis of numerous human diseases. In the liver, the first evidence of lncRNA, the H19, was found in fetal liver tissue. Cellular fractionation showed that H19 RNA is cytoplasmic but not associated with the translational machinery, thus it was not a classical mRNA [21]. Further, various lncRNAs were differentially expressed in cancers including in HCC [22–24]; however, their biological functions are complex and are not fully elucidated.

In HCC, lncRNAs could act as a modulator of the liver microenvironment and chronic liver diseases including viral infection, DNA and protein binding transcriptional activation, and miRNA and mRNA sponging, and encoding small peptides (comprehensively reviewed in [22]). Recent evidence showed also that the dysregulation of lncRNAs, such as LncMAPK6, LncSox4, and Linc00210, promoted the genesis of tumor-initiating cells (TICs), leading to HCC development [25–27]. Linc00210 drove the self-renewal and propagation of liver TICs through activating Wnt/β-catenin signaling, one of the most common dysregulating oncogenic pathways in HCC [26].

LncRNAs can be detected in the serum and plasma of an individual. Further, lncRNAs were reasonably stable for molecular analysis upon blood withdrawal. lncRNAs were not significantly degraded when samples were subjected to physical (prolonged room temperature incubation and multiple freeze-thaw cycles), chemical (low/high pH), and biological (RNase A) stress [28,29]. In pathological conditions, their presence and expression were altered thus can be used as a biomarker for diagnosis, disease monitoring, development of molecular-targeted therapy, and study of genetic heterogeneity [15]. A growing body of evidence showed that ncRNAs, including lncRNAs, may be primary genetic regulators in complex animals making them ideal diagnostic markers [17]. Here we reported lncRNAs for HCC diagnosis described in two or more studies by different research groups, including the HULC, LINC00152, UCA1, and MALAT1. Various lncRNAs useful in HCC diagnostics based on the calculation of the receiver operator characteristic (ROC) are shown in Table 1.

HULC (highly upregulated in liver cancer) is one of the first and most studied lncRNAs in HCC. Discovered in 2007, HULC was sequenced upon screening of the HCC-specific gene library of deregulated genes in HCCs, focal nodular hyperplasias, and cirrhosis utilizing cDNA arrays. HULC was also found to be present in peripheral blood cells [30]. Further studies showed multiple properties of HULC in promoting the growth and metastasis of HCC cells [31,32] and autophagy attenuated the sensitivity of HCC cells to chemotherapeutic agents via HULC/USP22/Sirt1 mechanism [33]. Several meta-analysis studies demonstrated that HULC can be used in the prognosis of various types of cancer. A higher HULC expression was associated with overall survival, lymph node metastasis, distant metastasis, and tumor stage [34–38].

Further research showed that circulating HULC in HCC patients could be used as a diagnostic marker, being highly up-regulated in patients with HCC compared to healthy individuals [39–41], with the area under the curve (AUC) of the receiver operator characteristic (ROC) curve around 0.80. Several studies; however, did not find up-regulation of HULC in HCC samples set [16,42]. A recent review summarized the role of HULC in carcinogenesis [43].

| n Samples a | Type | Exp | AUC b | SEN/SPE (%) b | AUC c | SEN/SPE (%) c | Ref |
|-------------|------|-----|-------|----------------|-------|----------------|-----|
| HULC        | 30/—/20 | plasma | up | 0.860 | na | - | - | [40] |
| HULC        | 129/76/93 | serum | up | 0.796 | 86/62 | 0.756 | 86/56 | [41] |
| HULC        | 66/—/52 | plasma | up | 0.780 | na | - | - | [39] |
| LINC00152   | 129/76/93 | serum | up | 0.895 | 78 / 89 | 0.877 | 81/83 | [41] |
| LINC00152   | 100/100/100 | plasma | up | 0.869 | na | 0.826 | na | [42] |
Table 1. Cont.

| n Samples | Type | Exp | AUC b | SEN/SPE (%) b | AUC c | SEN/SPE (%) c | Ref |
|-----------|------|-----|-------|---------------|-------|---------------|-----|
| LINC00152 | plasma | up | 0.850 | na            | -    | -             | [39]|
| MALAT1    | serum | up | 0.768 | 60/81         | 0.733 | 60/76         | [41]|
| MALAT1    | plasma | up | na    | na            | 0.666 | 51/89         | [44]|
| RP11–160H22.5 | plasma | up | 0.601 | na            | na    | na            | [45]|
| RP11–160H22.5 | plasma | up | 0.884 | na            | 0.859 | na            | [42]|
| XLOC014172 | plasma | up | 0.866 | na            | na    | na            | [45]|
| XLOC014172 | plasma | up | 0.759 | na            | 0.735 | na            | [42]|
| LINC00974 | plasma | up | 0.733 | -             | -     | 51/96         | [46]|
| UCA1      | serum | up | 0.858 | 81/75         | 0.809 | 67/81         | [41]|
| UCA1      | serum | up | 0.902 | 73/99         | 0.848 | 71/94         | [48]|
| UCA1      | serum | up | 0.861 | 93/82         | 0.728 | 61/74         | [49]|
| XIST      | mononuclear cells | up | 0.815 | 84/73         | 0.802 | 73/82         | [50]|
| XIST      | granulocytes | up | 0.829 | 73/84         | 0.782 | 72/83         | [51]|
| TSIX      | serum | up | 0.866 | 88/73         | na    | na            | [52]|
| PTTG3P    | serum | up | 0.785 | 83/61         | 0.768 | 83/57         | [41]|
| SPRY4-IT1 | serum | up | 0.808 | 77/71         | 0.768 | 77/68         | [41]|
| SPRY4-IT1 | plasma | up | 0.702 | 87/50         | 0.611 | 44/87         | [28]|
| UBE2CP3   | serum | up | 0.812 | 88/62         | 0.756 | 78/60         | [41]|
| LINC00161 | serum | up | 0.794 | 75/73         | na    | na            | [53]|
| LOC149086 | plasma | up | 0.759 | na            | na    | na            | [45]|
| RN7SL1 S fragment | plasma | up | 0.869 | 90/70         | -     | -             | [16]|
| SNHG1     | plasma | up | 0.920 | 65/95         | 0.740 | 65/95         | [54]|
| uc003wbd  | serum | up | 0.860 | na            | 0.700 | na            | [55]|
| AF085935  | serum | up | 0.960 | na            | na    | na            | [55]|
| CTBP      | serum | up | 0.910 | 91/89         | 0.830 | 91/89         | [56]|
| uc001ncr  | serum | up | 0.886 | 88/79         | 0.886 | 88/79         | [57]|
| AX800134  | serum | up | 0.925 | 93/87         | 0.925 | 93/87         | [57]|
| WRAP53    | serum | up | 0.896 | 85/82         | 0.787 | 85/71         | [57]|
| PTENP1    | serum | down | 0.602 | 89/71         | 0.530 | 89/23         | [41]|
| JPX       | plasma | down | 0.814 | 52/100        | -     | -             | [50]|

**circRNA**

| hsa_circ_000798 | pbmc | up | 0.70 | na | [58]|
| hsa_circ_104075 | serum | up | 0.97 | 96/98 | [59]|
| hsa_circ_0008234; circ-FOX1 | serum | up | 0.93 | na | [60]|
| CircSMARCA5 | plasma | down | 0.94 | 87/89 | 0.85 ch 0.71 cirr | 75/89 ch 77/64 cirr | [61]|
Another well studied lncRNA, the LINC00152 (long intergenic non-protein-coding RNA 52), was found through gene trapping technique, showing its role in the invasion and migration of HCC cells [67]. LINC00152 was involved in hepatocarcinogenesis by the activation of mTOR pathway [68]. It was hypomethylated in tumor tissues and human HCC cell lines [68] and during hepatocarcinogenesis [69]. In the blood, the expression level of LINC00152 increased from normal healthy control to chronic hepatitis B, liver cirrhosis, being highest in HCC [41,42]. Among other lncRNAs including HULC, LINC00152 was found to be the best diagnostic lncRNA with high AUC and sensitivity/specificity values [41]. Plasma and exosomal LINC00152 were also significantly elevated in gastric cancer patients compared with healthy controls, indicating its use in the cancer diagnosis [70].

Urothelial cancer associated 1 (UCA1) was first identified in bladder cancer [71]. UCA1 had been abundantly investigated as a non-invasive biomarker for various types of cancer, in particular for bladder cancer [72–75], both in blood and urine. The presence of UCA1 in body fluid was associated with tumor characteristics and patients’ prognosis. In HCC, it was up-regulated in HCC tissues and was associated with several clinical features and malignant behaviors in HCC [76,77]. A meta-analysis of seven studies validated the result, showing the association of UCA1 expression with tumor size, metastasis, and overall survival [78]. Several studies demonstrated the high expression of UCA1 in sera samples of HCC patients [41,47–49]. These studies showed a good AUC value > 0.800.

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) showed significant upregulation in neoplastic samples (HCC and highest in hepatoblastoma) compared to adjacent tumor and normal tissues [79]. Patients with high MALAT1 expression had a significantly increased risk of tumor recurrence after liver transplantation, pointing MALAT1 as an independent prognostic factor. MALAT1 inhibition in HepG2 cells reduced cell viability, motility, invasiveness, and increased the sensitivity to apoptosis [80]. Another analysis on HepG2 cells showed that MALAT1 involved in the HCC progression by sponging and competitive binding to miRNA-204, and released the suppression on sirtuin 1 (SIRT1) [81]. MALAT1 expression has been used in cancer diagnosis, including in bladder and lung cancer [82–84]. On the contrary, there is still limited information in HCC. Plasma MALAT1 was up-regulated in HCC compared to hepatic diseases (chronic viral hepatitis and NAFLD/NASH), and it can be used to distinguish HCC from other liver diseases [44]. A recent 2020 study showed that serum MALAT1 expression could distinguish HCC from healthy individuals and chronic hepatitis with AUC 0.768 and 0.733, respectively. However, these values were lower compared to HULC and LINC00152 [41].

RP11–160H22.5 was a novel lncRNA firstly detected in HCC upon global screening of lncRNA in plasma of HCC patients and the cancer-free individuals using a microarray platform. Microarray data was then confirmed by RT-PCR for 20 and 147 plasma HCC

### Table 1. Cont.

| n Samples | Type | Exp | AUC | SEN/SPE (%) | AUC | SEN/SPE (%) | Ref |
|-----------|------|-----|-----|-------------|-----|-------------|-----|
| hsa_circ_0003998 | plasma | up | 0.89 | 80/84 | 0.83 | 83/70 | [62] |
| hsa_circ_0027089 | plasma | up | 0.79 | 58/85 | 0.77 | 57/85 | [63] |
| hsa_circ_0051443 | exosome | down | 0.81 | na |  |  | [64] |
| hsa_circ_0004001 | serum | up | 0.73 | 76/81 |  |  | [65] |
| hsa_circ_0004123 | serum | up | 0.79 | 67/84 |  |  | [65] |
| hsa_circ_0075792 | serum | up | 0.76 | 81/69 |  |  | [65] |
| hsa_circ_009582 | plasma | up | 0.80 | na |  |  | [66] |
| hsa_circ_0037120 | plasma | up | 0.84 | na |  |  | [66] |
| hsa_circ_0140117 | plasma | up | 0.85 | na |  |  | [66] |

* Sample (HCC/chronic&cirrhosis/healthy) circulation-derived samples only; vs healthy control; vs chronic/cirrhosis; na = not available; AUC = area under the curve; * Calculated based on exoRBase data (http://www.exorbase.org/exoRBase/toIndex).
cases in training and validation sets, respectively. In the validation test; however, the AUC for this lncRNA was significantly decreased (0.900 to 0.601) in distinguishing HCC from the healthy control [45]. Another study comprised of 100 HCC cases supported the result with an increased AUC value to 0.884, indicating this lncRNA as a diagnostic biomarker for HCC [42]. Until now, there is no available data on its functional role in the HCC progression.

SPRY4 intronic transcript 1 (SPRY4-IT1) was up-regulated in HCC tissues and its high expression was associated with poor prognosis of the patients [85]. SPRY4-IT1 promoted the epithelial-mesenchymal transition (EMT) by up-regulating the transcription factor and EMT markers via interaction with EZH2 [86]. Recently, the expression of SPRY-IT1 was found to have diagnostic value to distinguish HCC patients from healthy controls and chronic hepatitis patients with AUC of 0.81 and 0.78, respectively [41]. Previously, SPRY4-IT1 was included in a lncRNAs panel together with MALAT1 and PCAT-1 for the non-invasive diagnosis and recurrence prediction of bladder cancer [87].

In several other studies, various lncRNAs, such as XLOC04172, LINCC0974, TSIX, UBE2CP3, SNHG1, uc003wbd, AF085935, CTBP, uc001ncr, AX800134, WRAP53, and JPX, were also able to distinguish HCC samples from healthy donors and patients with chronic hepatitis or cirrhosis with acceptable and even good AUC values of above 0.800 (Table 1).

2.2. Free-Circulating CircRNAs

Circular RNAs (circRNAs) were recently identified as an endogenous class of non-coding RNAs (ncRNAs) having multiples functions in the regulation of gene expression [88–90]. They were originated from a pre-mRNA undergoing the so-called “head-to-tail” or lariat-driven circulation, or back splicing process in which the splice donor site of a downstream exon of a protein-coding mRNA binds to the splice acceptor site of an upstream exon [91,92] to produce a circular product.

Most circRNAs derive from known protein-coding genes and consist of a single exon, multiple exons, exon, and intron (in this case the circular RNA is named ElciRNAs) or only introns (named ciRNAs) [93]. Generally, circRNAs localize in the cytoplasm [94], while ciRNAs and ElciRNAs reside in the nucleus where they can interact with U1 snRNP and RNA polymerase II to promote transcription of their parental genes. CircRNAs can compete also for the binding to the splicing machinery of their parental genes, thus inhibiting the full maturation [95]. Besides the roles in the nucleus, cytosolic circRNAs can bind and sequester specific proteins to appropriate subcellular positions, and participate in the modulation of some protein-protein or protein-RNA interactions [96]. Lastly, circRNAs are also known to work as competitive endogenous RNAs (ceRNAs) sponging intracellular microRNAs (miRNAs) [97,98]. As per lncRNA, circRNA can be detected in the serum and plasma of an individual. The use of circRNAs as a diagnostic tool for HCC is still recent, thus this review describes proposed circRNAs in single studies in current literature (Table 2). In the future, independent comparison to other studies will be needed.

### Table 2. Circular RNAs (circRNAs) expression in HCC.

| circRNA         | Host Gene                                      | Exp | Sponged miRNA | Source | n Samples | Ref |
|-----------------|------------------------------------------------|-----|---------------|--------|-----------|-----|
| hsa_circ_0005505 | Interleukin 1 Receptor Associated Kinase 3 (IRAK3) | up  |               | PBMC   | 30/-/72   | [58]|
| hsa_circ_0000798 | Bromodomain PHD Finger Transcription Factor (BPTF) | up  |               | PBMC   | 30/-/72   | [58]|
| hsa_circ_0001394 | TBC1 Domain Family Member 14 (TBC1D14)         | up  |               | PBMC   | 30/-/72   | [58]|
| hsa_circ_0001074 | Origin Recognition Complex Subunit 4 (ORC4)     | down|               | PBMC   | 30/-/72   | [58]|
| hsa_circ_0004771 | Nuclear Receptor Interacting Protein 1 (NRIP1)   | down|               | PBMC   | 30/-/72   | [58]|
| circRNA          | Host Gene                                      | Exp    | Sponged miRNA                  | Source  | n Samples | Ref   |
|------------------|-----------------------------------------------|--------|--------------------------------|---------|-----------|-------|
| hsa_circ_0067735 | Mediator Complex Subunit 12L (MED12L)         | down   |                                | PBMC    | 30/-/72   | [58]  |
| hsa_circ_104075  | Nucleoporin 153 (NUP153)                      | up     | miR-582-3p                     | serum   | 60/-/101  | [59]  |
| hsa_circ_0008234;| Forkhead Box P1 (FOXP1)                       | up     | miR-875-3p, and miR-421        | serum   | 16/-/30   | [60]  |
| hsa_circ_0003258;| Zinc Finger Protein 652 (ZNF652)              | up     | miR-29a-3p                     | exosomes| 33/-/33   | [99]  |
| hsa_circ_0010090;| Filamin Binding LIM Protein 1 (FBLIM1)        | up     | miR-338                        | exosomes| 33/-/33   | [100] |
| hsa_circ_101237  | Cyclin-Dependent Kinase (CDK8)                | up     |                                | serum   | 124/-/234 | [101] |
| CircSMARCA5      | Regulator of Chromatin, Subfamily A, Member 5 (SMARCA5) | down   |                                | plasma  | 103/117+143/135 | [61] |
| circZEB1.33      | Zinc Finger E-Box Binding Homeobox 1(ZEB1)    | up     | miR-200a-3p                    | serum   | 30/-/64   | [102] |
| hsa_circ_0003998 | Guanine Nucleotide Exchange Factor 2 (ARFGEF2) | up     |                                | plasma  | 50/50/100 | [62]  |
| hsa_circ_0027089 | Prostaglandin E Synthase 3 (PTGES3)          | up     |                                | plasma  | 72/64/84  | [63]  |
| hsa_circ_0077930 | Abelson Helper Integration Site 1 (AH1)       | up     |                                | plasma  | -/24/24   | [63]  |
| hsa_circ_0001818 | Ubiquitin Protein Ligase E3 Component N-Recognin 5 (UBR5) | up     |                                | plasma  | -/24/24   | [63]  |
| hsa_circ_0026337 | Sodium Voltage-Gated Channel Alpha Subunit 8 (SCN8A) | up     |                                | plasma  | -/24/24   | [63]  |
| hsa_circ_0011883 | Palmitoyl-Protein Thioesterase 1 (PPT1)       | down   |                                | plasma  | -/24/24   | [63]  |
| hsa_circ_0001070 | R3H Domain Containing 1 (R3HDM1)             | down   |                                | plasma  | -/24/24   | [63]  |
| hsa_circ_0064428 | Solute Carrier Family 6 Member 6 (SLC6A6)    | down   |                                | plasma  | 56/64(high vs. low TILs) | [103] |
| hsa_circ_0055538 | Required for Meiotic Nuclear Division 5 Homolog A (RMND5A) | down   |                                | plasma  | 56/64(high vs. low TILs) | [103] |
| hsa_circ_0065964 | ABHD14A-ACY1 Readthrough                    | up     |                                | plasma  | 56/64(high vs. low TILs) | [103] |
| hsa_circ_0011386 | Eukaryotic Translation Initiation Factor 3 Subunit 1 (EIF3I) | up     |                                | plasma  | 56/64(high vs. low TILs) | [103] |
| hsa_circ_0044172 | Kinase Kinase Kinase 14 (MAP3K14)             | up     |                                | plasma  | 56/64(high vs. low TILs) | [103] |
| hsa_circ_0010882 | Ribosomal Protein L1 (RPL1)                  | up     |                                | plasma  | 56/64(high vs. low TILs) | [103] |
| hsa_circ_0000199,| AKT Serine/Threonine Kinase 3 (AKT3)          | up     |                                | exosomes| 100/-/124 | [104] |
| hsa_circ_0088030,| Prostaglandin Reductase 1 (PTGR1)             | up     | miR-449a                       | exosomes| 47/-/82   | [105] |
| hsa_circ_0008043,| Prostaglandin Reductase 1 (PTGR1)             | up     | miR-449a                       | exosomes| 47/-/82   | [105] |
Table 2. Cont.

| circRNA         | Host Gene                                      | Exp | Sponged miRNA       | Source  | n Samples^a | Ref  |
|-----------------|------------------------------------------------|-----|---------------------|---------|-------------|------|
| circUHRF1       | Ubiquitin Like with PHD and Ring Finger Domains 1 (UHRF1) Homo Sapiens Trafficking | up   | miR-449-5p          | exosomes| 20/-/240    | [106]|
| hsa_circ_0051443| Protein Particle Complex 6A (TRAPPC6A)          | down| miR-331-3p          | exosomes| 60/-/60     | [64] |
| hsa_circ_0066659| Transmembrane Protein 45A                      | up   | miR-665             | exosomes| 30/-/30     | [107]|
| hsa_circ_0004001| ETS Variant Transcription Factor 6 (ETV6)      | up   |                     | serum   | 40/-/71     | [65] |
| hsa_circ_0004123| CDC Like Kinase 1 (CLK1)                       | up   |                     | serum   | 40/-/71     | [65] |
| hsa_circ_0075792| Lysine Demethylase 1B (KDM1B)                  | up   |                     | serum   | 40/-/71     | [65] |
| hsa_circ_0009582| Arginine-Glutamic Acid Dipeptide Repeats (RRE) | up   |                     | plasma  | 200/200/200 | [66] |
| hsa_circ_0037120| Rhomboid 5 Homolog 1 (RHBDF1)                 | up   |                     | plasma  | 200/200/200 | [66] |
| hsa_circ_0140117| Connector Enhancer of Kinase Suppressor of Ras 2 (CNKSR2) | up   |                     | plasma  | 200/200/200 | [66] |
| hsa_circ_0000976| Hippocalcin Like 1 (HPCAL1)                   | up   |                     | plasma  | 179/186+180/600 | [108]|
| hsa_circ_0007750| Rab Geranylgeranyltransferase Subunit Alpha (RABGGA) | up   |                     | plasma  | 179/186+180/600 | [108]|
| hsa_circ_0139897| Myotubularin 1 (MTM1)                        | up   |                     | plasma  | 179/186+180/600 | [108]|

^a Sample (HCC/chronic&cirrhosis/healthy), TILs = tumor-infiltrating lymphocytes.

Besides its role in activating yes1 associated transcriptional regulator (YAP1) as a ceRNA to bind the YAP inhibitor miR-582-3p, the hsa_circ_104075 was found to be up-regulated in serum of HCC patients, compared to healthy controls. It showed better performances as a predictor for HCC (AUC 0.973) compared to other non-coding RNAs, including miRNAs, and classical protein biomarkers such as AFP (AUC 0.750) [59]. Likewise, the circRNA generated from the Forkhead Box P1 gene (FOXP1), circ-FOXP1, was highly expressed in the serum of HCC patients, being consistent with its expression in tumoral tissue [60]. Considering its molecular role as ceRNA for two oncosuppressor miRNAs, miR-875-3p and miR-421, the high levels of circ-FOXP1 were associated with larger tumors, microvascular invasion, and lower survival. Despite being analyzed in a low number of samples, it was able to distinguish cancer patients from controls with an AUC of 0.930, suggesting some potential value as a diagnostic biomarker in HCC [60].

In 2018, Gong et al. [102] identified circ-ZEB1.33 being significantly higher in serum of HCC patients compared to healthy controls, and its levels were positively correlated with the increase of TMN stage, being higher in the III–IV stage compared to the I–II stage. Based on this evidence, the authors suggested serum circ-ZEB1.33 as a diagnostic biomarker for HCC, as it was up-regulated also in tumor tissues. In HCC, circ-ZEB1.33 sponged miR-200a-3p ensuring the expression of the miR-200a-3p target, cyclin dependent kinase 6 (CDK6) [102], that had an active role in phosphorylating the tumor suppressor protein, retinoblastoma transcriptional corepressor 1 (Rb1), thus promoting the cell cycle enter into S phase.

The investigation of the circSMARCA5 expression in HCC plasma samples, as well as in precancerous conditions, such as cirrhosis and hepatitis B and C, evidenced the progressive down-regulation of this circRNA from hepatitis to cirrhosis and HCC [61]. ROC curve analysis evidenced the potential of this circRNA in distinguishing patients with hepatitis or cirrhosis from patients with HCC, especially those patients with AFP levels below 200 ng/mL. Besides, the comparison with healthy subjects further proved the value of circSMARCA5 in distinguishing HCC patients from controls. Tissue analysis proved the tumor origin of circSMARCA5, in which it is supposed to promote metalloproteases
expression (MMP7 and MMP9), as evidenced from in vitro experiments conducted in Huh7 cells. Indeed, the decrease of circSMARCA5 in tumors was correlated with invasion, tumor differentiation, and TNM stage [61].

On the contrary, the plasma levels of hsa_circ_0003998 in HCC patients were significantly higher compared to the levels in hepatitis B patients and healthy controls, being able to significantly distinguish HCC patients from the other two groups with an AUC greater than 0.80. Importantly, the plasma levels of hsa_circ_0003998 were significantly correlated with higher serum AFP level, larger tumor diameter, microvascular invasion (MVI), and lower differentiation level [62].

Three circRNAs, hsa_circ_0004001, hsa_circ_0004123, and hsa_circ_0075792, investigated in the serum of 71 HCC patients, showed marked upregulations compared to 40 healthy individuals [86]. Despite this study being performed in whole serum RNA extracts, consistency was found with the data retrieved from the exoRBase database [109] (http://www.exorbase.org/exoRBase/toIndex), which include exosomal circRNAs from 21 HCC patients. Indeed, the diagnostic potential of these three candidates was also verified through ROC curve analysis, showing the discriminatory potential of the circRNAs between HCC patients and controls with an AUC always above 0.70 [65].

Three recent and comprehensive studies investigated the circRNAs profile in plasma samples of HBV-related HCC and controls. In one of these studies, 13,617 circRNAs were profiled through microarray in 10 HBV-related HCC patients, compared to five patients with HBV-related cirrhosis [63]. They identified 157 up-regulated and 161 downregulated circRNAs in HCC compared to cirrhosis, where 86 were able to cluster HCC samples vs. cirrhosis samples. In the training phase, six circRNAs were confirmed to be differentially expressed between HCC and cirrhosis, with hsa_circ_0077930, hsa_circ_0027089, hsa_circ_0001818, and hsa_circ_0026337 being up-regulated, while hsa_circ_0011883 and hsa_circ_0001070 were downregulated. In particular, one of them, hsa_circ_0027089 was further validated in a cohort of 64 HCC patients, 40 cirrhosis patients, and 72 healthy individuals, resulting in significant up-regulation in the plasma of patients with HCC compared to the other groups [63]. Besides, its diagnostic value in distinguishing HCC from cirrhosis was supported by a ROC curve analysis that found an AUC of 0.77 and 0.79, when comparing HCC patients vs. patients with cirrhosis and healthy controls, respectively [63].

Similarly, Wu et al. [66], through a microarray approach, identified five circRNAs that were significantly up-regulated in HCC patients compared to patients with CHB. They were decreased after surgical removal of the nodules, thus underlying a possible direct link with the presence of a tumor. Among the five candidates, hsa_circ_0009582, hsa_circ_0037120, and hsa_circ_0140117 resulted significantly up-regulated in the validation group, consisting of 200 HCC patients compared to 200 patients with CHB, and 200 healthy controls, and the increase extent of positively was correlated with the progression of the disease [66]. Importantly, the combination of these three candidates was able to significantly distinguish HCC patients from healthy controls with a positive predictive value (PPV) and negative predictive value (NPV) of 80% and 95%, respectively, and from CHB patients with a PPV and NPV of 84% and 80%, respectively [66]. Various circRNAs useful in HCC diagnostics based on the calculation of the ROC curve are shown in Table 1.

A different panel of plasma circRNA, named CircPanel and consisting of hsa_circ_0000976, hsa_circ_0007750, and hsa_circ_0139897, was suggested by Yu and colleagues for the diagnosis of HBV-related HCC (n = 600), even at early stages with solitary small nodules less than 3 cm [108]. In addition, the CircPanel showed higher accuracy than AFP in distinguishing individuals with HCC from non-HCC subjects, as well as seen for IncRNAs. In many studies, the use of IncRNA expression level, especially the LINC00152, was found to have a better diagnostic power compared to that of AFP alone. However, majority of the cited studies, if not all, showed that the combination between various ncRNAs and serum AFP level increased the diagnostic value (Table 3).
Table 3. List of small non-coding RNA (sncRNA) panel for HCC diagnosis and in combination with alpha-fetoprotein (AFP).

| sncRNA Panel | AUC \textsuperscript{a} | sncRNA Panel + AFP | AUC \textsuperscript{a} | Ref |
|--------------|-----------------|------------------|-----------------|-----|
| IncRNA       |                 |                  |                 |     |
| -            | -               | LINC00152, PTENP1, UCA1, and AFP | 0.912 | [41] |
| LINC00152, RP11-160H22.5, XLOC014172 | 0.985 | LINC00152, RP11-160H22.5, XLOC014172, AFP | 0.986 | [42] |
| HULC, LINC00152 | 0.870 | HULC, LINC00152, AFP | 0.890 | [39] |
| SNHG1        | 0.920           | SNHG1, AFP       | 0.970           | [54] |
| PVT1, uc002mbe.2 | 0.764 | PVT1, uc002mbe.2, AFP (20ng/mL) | 0.831 | [110] |
| RP11–160H22.5, XLOC_014172, LOC149086 | 0.896 | -               | -               | [45] |
| uc001mcr, AX800134 | 0.949 | -               | -               | [57] |
| SPRY4-IT1    | 0.702           | SPRY4-IT1, AFP   | 0.800           | [28] |
| UCA1, WRAP53 |                 | UCA1, WRAP53, AFP | 0.905 | [49] |
| JPX          |                 | JPX, AFP         |                 | [50] |
| CircRNA      |                 |                  |                 |     |
| hsa_circ_0004001+hsa_circ_0004123+hsa_circ_0075792 | 0.89 |                |                 | [65] |
| hsa_circ_0009582+hsa_circ_0140117 | Sen/spe 80/95 vs. CH | 84/80 vs. cirr |                | [66] |
| hsa_circ_0007750+hsa_circ_0139897 | 0.860 |                |                 | [108] |
| hsa_circ_0027089 | 0.790 | hsa_circ_0027089, AFP | 0.800 | [63] |

\textsuperscript{a} vs healthy control.

3. Exosomal-Derived IncRNAs and CircRNAs

Besides the presence of cfRNA in plasma or serum, various studies indicated that cfRNAs exist in extracellular vesicles (EVs), such as exosomes and microvesicles (Figure 1). EVs act as a carrier of heterogeneous cargo of proteins, signaling lipids, and nucleic acids from donor cells to recipient cells, and thus had been proposed to serve as mediators of cell-to-cell communication.

Exosomes are frequently associated with cancer. They are the smallest subtype of EVs with 30 to around 100 nm in diameter, surrounded by a phospholipid bilayer and as spherical- to cup-shaped nanoparticles. They have specific surface molecular characteristics CD9, CD81, and CD63, LAMP1, and TSG101 [111,112]. Exosomes are formed by the inward budding of multivesicular bodies and are released into the microenvironment, interstitial spaces, and bodily fluids following the fusion with the plasma membrane [112]. Studies showed the presence of RNAs in EVs, both coding and non-coding RNAs (reviewed in [113]). The detection of exosomal-ncRNA is a good approach, since RNAs inside the exosome are protected from RNases, thus it can be presumed that the integrity and function of the RNAs are not altered [70,114].

Since ncRNAs are enriched and stable in exosomes they were considered a class of circulating RNA to be included in the biomarker discovery studies. The first evidence in this regard derives from the study of Li and colleagues [115] that identified a profile of exo-circRNAs able to distinguish colon cancer patients from healthy controls. Further evidence then identified circRNAs in HCC-associated exosomes, opening new perspectives for the identification of circulating RNAs as biomarkers for this disease.
acids from donor cells to recipient cells, and thus had been proposed to serve as mediators of cell-to-cell communication. Exosomes are frequently associated with cancer. They are the smallest subtype of EVs with 30 to around 100 nm in diameter, surrounded by a phospholipid bilayer and as spherical- to cup-shaped nanoparticles. They have specific surface molecular characteristics CD9, CD81, and CD63, LAMP1, and TSG101 [111,112]. Exosomes are formed by the inward budding of multivesicular bodies and are released into the microenvironment, interstitial spaces, and bodily fluids following the fusion with the plasma membrane [112]. Studies showed the presence of RNAs in EVs, both coding and non-coding RNAs (reviewed in [113]). The detection of exosomal-ncRNA is a good approach, since RNAs inside the exosome are protected from RNases, thus it can be presumed that the integrity and function of the RNAs are not altered [70,114].

Since ncRNAs are enriched and stable in exosomes they were considered a class of circulating RNA to be included in the biomarker discovery studies. The first evidence in this regard derives from the study of Li and colleagues [115] that identified a profile of exo-circRNAs able to distinguish colon cancer patients from healthy controls. Further evidence then identified circRNAs in HCC-associated exosomes, opening new perspectives for the identification of circulating RNAs as biomarkers for this disease.

Cytosolic lncRNA and circRNA can be sorted into the exosomal cargo to be released together with the multitude of other non-coding regulatory RNAs, mRNAs, and proteins into the bloodstream. Thousands of different ncRNAs are known to be included in exosomes derived from several cancer types, including HCC [109].

3.1. Exosome-Derived lncRNAs

A recent study by Huang using RNA sequencing identified around 8500 lncRNAs that were differentially expressed (DE-) in plasma exosomes between HCC patients and healthy controls [116]. Here, the authors analyzed the best five candidates of novel DE-lncRNAs (lnc544, lnc239, lnc959, lnc171, and lnc85), comparing their expression with HCC cell lines and exosome-derived from cell lines. From these lncRNAs, the inhibition of lnc85 resulted in the impairment of cell proliferation, and it decreased the migration in HCC cells. Functional analysis showed that lnc85 promoted proliferation, metastasis, and apoptosis of HCC cells by regulating the expression of miR-324-5p-associated target genes, thus showing this lncRNA as the sponge of miR-324-5p [116].

Another 2020 microarray study was reported by Lu et al. comparing exosomes derived from four groups of healthy control, chronic hepatitis, HCC without metastasis, and HCC with metastasis. Based on a Venn diagram of shared lncRNAs, they proposed six lncRNA candidates as biomarker predictors of tumorigenesis and metastasis of HCC, the ENSG00000248932.1, ENST00000440688.1, and ENST00000457302.2 LOC_001120, ENSG00000243766.2, AC058791.2, and TCONS_0003661. In a larger data set, three of

Figure 1. Circulating long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) for hepatocellular carcinoma (HCC) diagnosis. Both lncRNAs and circRNAs can be found as free-circulating molecules or encapsulated into exosomes. Circulating cancer cells and immune cells can release exosomes contributing to the variety of circulating non-coding RNAs (ncRNAs) present in the bloodstream.
the first lncRNAs were then confirmed in another 180 HCC cases as a validation set, confirmed with a continuously increasing level in healthy control, chronic hepatitis, and HCC groups. Interestingly, these lncRNAs also showed diagnostic values, with the AUC of 0.794, 0.571, and 0.538 for ENSG00000248932.1, ENST00000440688.1, and ENST00000457302.2, respectively. The combinations of these three lncRNAs showed an AUC of 0.838 [117].

Besides novel lncRNAs discovery by global screening, comparison studies, also supported by literature review, have demonstrated the presence of other lncRNAs in exosomes as a diagnostic tool. As a promising lncRNA, HULC has been demonstrated to be a strong diagnostic biomarker for HCC in various studies, as mentioned above. The presence of HULC in circulation can be derived also from exosomes. HULC expression in serum exosomes was related to its expression in HCC tissues, being higher in HCC (n = 30) compared to healthy controls. Both serum exosome and tissue level were correlated with the tumor-node-metastasis (TNM) classification. In HCC cell lines HepG2 and SMMC7721, the upregulation of HULC promoted HCC cell growth and invasion and repressed apoptosis, and at the same time decreased (sponged) the level of miR-372-3p [118].

In 2018, a study from Sun et al. showed LINC00161, together with LINC00462 and UCA1, being lncRNA upregulated in HCC serum samples (56 HCC vs. 56 controls; AUC = 0.794). Further examination on the exosome-enriched fraction (30–150 nm) showed that the levels of LINC00161 were upregulated in patients with HCC in contrast to controls (p < 0.05). No statistical significance was detected for the expression of LINC00161 in HCC urine and serum exosome-free samples compared with controls [99]. Previously, LINC00161 was shown to be expressed significantly higher in HCC tissues and its high expression was related to a poor prognosis [119].

The selection of lncRNA-RP11-583F2.2 targeting hsa-miR-1298 was based on bioinformatics tools named TCNG and NRED, with a high number of target genes. Exosomal lncRNAs were extracted from sera samples of 60 HCC, 42 chronic HCV, and 18 healthy donor individuals. Compared with the non-malignant groups, the malignant group (HCC) had a higher expression of lncRNA-RP11-583F2.2, with diagnostic power to distinguish HCC with healthy donors with AUC = 0.946 and sens/spec 97/92%. The use of this lncRNA was shown to reduce false-negative results, as compared to AFP alone [120].

Recently, the same group showed another related lncRNA, the lnc-RNA RP11-156p1.3 being significantly altered in HCC patients compared to chronic HCV patients and healthy controls. Functional analysis of this lncRNA was demonstrated by the use of CRISPR cas9 knock-out in HepG2 cells, which showed that the level of the genetic network was reversed and the protein levels of TNFα and NFKβ were decreased, together with a significant decrease in cell count and viability. It indicated that lnc-RNA RP11-156p1.3 can be a promising therapeutic target as well as a diagnostic tool [121].

The effect of HCV in exosomes was presented by lncRNA-HEIH. By using groups of chronic hepatitis C, HCV-related cirrhosis, and HCV-related HCC, the lncRNA-HEIH expression was found increased in the serum and exosomes of HCC groups. Interestingly, the ratio of lncRNA-HEIH expression in serum versus exosomes was decreased compared to patients with chronic hepatitis [122]. In in vitro model, HEIH is involved in HCC cell growth and metastasis through the regulation of several miRNAs, such as miR-199a-3p and miR-98-5p, and the deactivation of AKT and mTOR pathways [123–125].

### 3.2. Exosome-Derived CircRNAs

Through microarray profiling of plasma exosomal circRNAs, comparing three HCC patients with three healthy controls, Chen and colleagues identify a signature of 36 circRNAs able to cluster HCC and controls in two separated groups [64]. Among the 28 downregulated circRNAs in HCC, circ-0051443 was further confirmed as a biomarker candidate able to distinguish 60 HCC patients from controls (AUC = 0.809). Authors hypothesized a protective role for this circRNA, since its exosomal levels in exosomes of both healthy subjects and in normal cells circ-0051443 levels were high. Interestingly, its expression levels were four times higher in exosomes compared to producer cells [64]. Further investigations
evidenced how circ-0051443 protects the cells from malignant transformation by sponging miR-331-3p [107] responsible for the targeting of B cell lymphoma (Bcl)-2 homologous antagonist/killer (Bak1), an essential cell death regulator, which initiates mitochondria-mediated apoptosis [126].

Despite the work from Li [99] being focused on the identification of the molecular effects derived from the transfer of exosomal circ-ZNF652 in cancer recipient cells, where the miR-29a-3p sponging promoted proliferation, migration, invasion, and glycolysis by affecting the guanylyl cyclase domain containing 1 (GUCD1) expression, it provided also evidence of circ-ZNF652 being higher in exosomes collected from cancer patients, compared to controls [99]. However, this evidence was derived from the analysis of 33 HCC samples and no further investigation of its diagnostic or prognostic potential was conducted.

Likewise, the expression of circ-FBLIM1 was investigated in 30 HCC samples compared to 25 healthy volunteers by Lai and colleagues [100]. The observation of high circ-FBLIM1 levels in HCC patients led the authors to hypothesize a relevant role for this circRNA in tumors. Their findings verified that circFBLIM1 contributed to the progression and glycolysis of HCC by sponging miR-338 and determining the consequent upregulating of LDL Receptor Related Protein 6 (LRP6) [100]. Despite the evidence of the high levels of circ-FBLIM1 in HCC exosomes, its value as a tumor biomarker should be further validated.

The circulating exosomal circAKT3, derived from the back splicing of exon 8–11 of the AKT3 gene, was significantly higher in HCC patients compared to healthy subjects. in patients with HCC, circAKT3 was associated with tumor sizes, microinvasion, and higher AFP levels, suggesting its possible role in this disease [104]. Besides the differential expression between healthy subjects and HCC patients, exosomal circAKT3 showed also some prognostic potential. Higher levels were associated with shorter survival time and shorter recurrence-free survival rate after surgery. Indeed, patients with high levels of exosomal circAKT3 showed higher recurrence (HR, 3.14; 95%CI 1.29–6.21, \( p = 0.012 \)) and higher mortality (HR, 1.89; 95% CI, 1.04–3.01) [104]. This evidence suggested not only a possible role of this circRNA as a diagnostic biomarker for HCC derived from different etiologies, but also for the follow-up of patients receiving surgery to early identify recurrence episodes.

Intriguing is the role of exosomal circPTGR1 in HCC. In their study, Wang and colleagues identified three circRNAs, hsa_circ_0008043, hsa_circ_0003731, and hsa_circ_0088030, collectively named circPTGR1, since they are all transcribed from the same gene (prostaglandin reductase 1, PTGR1). They were significantly enriched in exosomes released by high metastatic LM3 cells, compared to HepG2 (a non-metastatic cell line) and 97L cells (a low-metastatic cell line) [105]. Interestingly, the incubation of HepG2 and 97L cells with LM3-derived exosomes enhanced the cell migration and invasion abilities of both cell lines, however, without affecting their proliferation, apoptosis, or cell cycle. When investigated in serum exosomes collected from HCC and healthy subjects, hsa_circ_0008043 and hsa_circ_0088030, but not hsa_circ_0003731, showed an up-regulation in HCC patients, compared to controls [105]. In addition, circPTGR1 differed significantly between clinical stages of HCC, being higher at TNM stage III. In agreement with these findings, the high levels of circPTGR1 was also associated with poorer survival. In vitro investigations identified the role of circPTGR1 in promoting MET proto-oncogene receptor tyrosine kinase (MET) expression by competing with the binding to miR449a, thus facilitating cellular survival, migration, and invasion [105].

Similar to the aforementioned example, circUHRF1 showed a clear association with the presence of a tumor [106]. It was up-regulated in exosomes isolated from 240 HCC patients compared to 20 healthy individuals. Moreover, its expression decreased with the surgical removal of the tumoral portion, and re-increased with tumor recurrence phenomena, thus suggesting circUHRF1 as a hallmark of liver cancer. In their study, Zhang and colleagues unrevealed one of the possible functions of the circulating exosomal circUHRF1. They found NK cells able to internalize HCC-derived exosomes loaded/enriched in circUHRF1. NK cells have been verified to have cytotoxic effects against tumor cells...
in several cancers [127,128], this activity was largely influenced by the expression of the inhibitory molecule programmed cell death 1 (PD1). The T cell immunoglobulin and mucin domain 3 (TIM-3) is an important coinhibitory molecule and is also expressed on NK cell and its expression is higher in NK cells from tumor patients than from healthy donors [129]. In this scenario, exosomal circUHRF1 internalized by NK cells could sustain the TIM-3 expression by sponging its inhibitor miR-449-5p [106], resulting in a suppression of the production of interferon γ (IFN-γ) and tumor necrosis factor α (TNF-α) by the cytotoxic NK cells [106]. These observations provide evidence of circUHRF1 as cancer-related circRNA able to identify patients that are likely to better respond to anti-PD1 treatments.

In exosomes collected from 30 HCC patients, the circTMEM45A (hsa_circ_0066659) was approximately four times higher compared to the exosomes collected from 30 healthy individuals. Despite no clinical significance was given to the high exosomal circTMEM45A levels, in vitro experiments proved the oncogenic role of this circRNA in HCC cells. Indeed, it had a role in sponging miR-665, thus determining tumor growth due to the up-regulation of the miR target insulin-like growth factor 2 (IGF2) [107].

4. Circulating Cells-Derived IncRNAs and CircRNAs

The peripheral blood mononuclear cells (PBMCs) include a variety of leukocyte subpopulations, such as monocytes, natural killer cells, T lymphocytes, B lymphocytes, and dendritic cells. Since the well-established role of immune cells in cancers, including HCC [130], many studies proposed PBMCs as a source of information related to the presence of the tumor, including prognosis and treatment response [131–133] for other molecules, also the altered expression profile of ncRNAs in PBMCs might provide some promising biomarkers for tumor diagnosis and management.

XIST and TSIX are two IncRNAs with a pivotal role in X chromosome inactivation (XCI). XIST (X inactive-specific transcript) was firstly reported in 1991, expressed specifically from inactive X chromosomes [134]. In 1999, TISX was discovered as gene antisense to XIST. It is a 40 kb RNA originating 15 kb downstream of XIST and transcribed across the XIST locus [135]. In HCC, XIST was involved in the cancer progression by sponging various miRNAs (e.g., miR-200b-3p, miR-155-5p, and miR-194-5p) [136,137]. In 2017, Ma et al. showed an increase of XIST expression in PBMC and granulocytes in HCC female patients. XIST had a significant discriminatory power to differentiate early-stage HCC group with healthy, CHB, and cirrhosis, compared to AFP [51]. They also showed that Jpx, another lncRNA, could be delivered from HCC cells to blood cells via exosomes and activate Xist expression of blood cells [51].

Hox antisense intergenic RNA (HOTAIR), is an oncogenic molecule localized to the HOXC gene cluster. It is one of the HCC markers since patients with high HOTAIR expression had significantly poorer prognoses and larger primary tumor size [138,139]. A study from Fujisaka [140] showed that CCL2, a monocyte chemoattractant protein 1, was differentially expressed in the HOTAIR-expressing liver cells. A co-culture of these cells with PBMC increased the proportion of CD14+HLA-DR+CD68+ macrophages [140].

Lei and colleagues [58] identified 58 circRNAs significantly dysregulated in the PBMCs collected from HCC patients compared with those of the healthy individuals. Six of them were further validated in 72 PBMCs samples from HCC patients and 30 from control subjects confirming the up-regulation of hsa_circ_0005505, hsa_circ_0000798, and hsa_circ_0001394 and the downregulation of hsa_circ_0001074, hsa_circ_0004771, and hsa_circ_0067735 in HCC-derived PBMC, compared to healthy controls. The increase of hsa_circ_0000798 in PBMC was also associated with a shorter survival rate. Patients with high has_circ_0000798 had a median survival of 10 months compared to the 24 months of patients having low levels has_circ_0000798. Additionally, some diagnostic potential was observed for circ_0000798 that discriminated HCC patients from healthy individuals with an AUC of 0.703 [58].
5. Future Message

Liquid biopsy for early HCC detection is a potent non-invasive strategy that leads to better clinical management of the disease. Scientific evidence in recent years indicated that lncRNAs and circRNAs can be good biomarkers due to their reliability and easy detection by PCR-based technology.

Some considerations are needed to use their potentials as HCC biomarkers. First is the standardization among laboratories. One of the problems of the RNA expression is due to technical variations among laboratories, including the reference genes used, the protocol, and the determination of cut-off value. The second problem is whether the circulating RNAs could specifically represent liver pathology, such as AFP which is a characterized liver protein. Several lncRNAs reviewed in this article are common in cancers, and not specific to HCC only. The third is whether these RNAs can be used to detect early stages of HCC (BCLC 0 and A), also with a single small nodule. Early diagnosis would allow the physician to apply curative treatments increasing the good prognosis of the patients. And last but not least, is the determination of which RNAs are the best marker, whether a single RNA, multiple RNA panels, and scoring values can be the strongest diagnostic determinant of HCC. Until the writing of this article, there is still substantial growth in the public database on the function and possible use of dozens lncRNAs and circRNAs, both in the tissues and in the circulation as a cancer diagnosis biomarker.

In summary, biomedical technology is growing fast and the discovery of cancer biomarkers is abundant. It is important to cross-check and validate these markers with various cohorts of patients representing high variabilities of HCCs, including patients with different etiologies, HCC cellular profiles, and stages of cancer. It should be noted whether the current therapy regimen applied to patients could alter the expression of these RNAs, thus providing their potential as a biomarker for patient follow-up and surveillance.

Author Contributions: C.H.C.S., D.P., and C.T. conceived the idea. C.H.C.S., L.K.D.C., C.T., and D.P. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: C.H.C.S. is funded by 2020 grant of the Fondazione Umberto Veronesi, Milan, Italy, and L.K.D.C. by a fellowship of the Department of Science and Technology and the Philippine Council for Health Research and Development (DoST-PCHRD). The cost of the study was supported by an intramural research grant of the Fondazione Italiana Fegato.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data sharing not applicable. No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: All authors declared that there are no conflicts of interest.

References

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef] [PubMed]
2. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Mathers, C.; Parkin, D.M.; Pineros, M.; Znaor, A.; Bray, F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 2018, 144, 1941–1953. [CrossRef] [PubMed]
3. Kulik, L.; El-Serag, H.B. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology 2019, 156, 477–491. [CrossRef] [PubMed]
4. Torres, M.C.P.; Bodini, G.; Furnari, M.; Marabotto, E.; Zentilin, P.; Strazzabosco, M.; Giannini, E.G. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers 2020, 12, 1422. [CrossRef] [PubMed]
5. SanGiovanni, A.; Prati, G.M.; Fasani, P.; Ronchi, G.; Romeo, R.; Manini, M.; Del Ninno, E.; Morabito, A.; Colombo, M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006, 43, 1303–1310. [CrossRef]
6. Galle, P.R.; Forner, A.; Llovet, J.M.; Mazzaferro, V.; Piscaglia, F.; Raoul, J.-L.; Schirmacher, P.; Vilgrain, V. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018, 69, 182–236. [CrossRef]
7. Heimbach, J.K.; Kulik, L.M.; Finn, R.S.; Sirlin, C.B.; Abecassiss, M.M.; Roberts, L.R.; Zhu, A.X.; Murad, M.H.; Marrero, J.A. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology* **2018**, *67*, 358–380. [CrossRef]

8. Omata, M.; Cheng, A.-L.; Kokudo, N.; Kudo, M.; Lee, J.M.; Jia, J.; Tateishi, R.; Han, K.-H.; Chawla, Y.K.; Shiina, S.; et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. *Hepatol. Int.* **2017**, *11*, 317–370. [CrossRef]

9. Forner, A.; Llovet, J.M.; Bruix, J. Hepatocellular carcinoma. *Lancet* **2012**, *379*, 1245–1255. [CrossRef]

10. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; De Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; et al. Sorafenib in Advanced Hepatocellular Carcinoma. *N. Engl. J. Med.* **2008**, *359*, 378–390. [CrossRef]

11. Cabibbo, G.; Enea, M.; Attanasio, M.; Bruix, J.; Craxi, A.; Cammà, C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. *Hepatology* **2009**, *51*, 1274–1283. [CrossRef] [PubMed]

12. Wang, Z.; Zhang, K.-H. New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma. *Front. Oncol.* **2020**, *10*, 1316. [CrossRef]

13. Farinati, F.; Marino, D.; De Giorgio, M.; Baldan, A.; Cantarini, M.; Cursaro, C.; Rapaccini, G.; Del Poggio, P.; Di Nolfo, M.A.; Benvengu, L.; et al. Diagnostic and Prognostic Role of alpha-Fetoprotein in Hepatocellular Carcinoma: Both or Neither? *Am. J. Gastroenterol.* **2006**, *101*, 524–532. [CrossRef]

14. Gupta, S.; Bent, S.; Kohlves, J. Test Characteristics of alpha-Fetoprotein for Detecting Hepatocellular Carcinoma in Patients with Hepatitis C. *Ann. Intern. Med.* **2003**, *139*, 46–50. [CrossRef] [PubMed]

15. Mocan, T.; Simao, A.L.; Castro, R.E.; Rodrigues, C.M.; Slomka, A.; Wang, B.; Strassburg, C.P.; Wöhler, A.; Willms, A.G.; Korner, M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? *J. Clin. Med.* **2020**, *9*, 1541. [CrossRef]

16. Gupta, S.; Bent, S.; Kohlves, J. Test Characteristics of alpha-Fetoprotein for Detecting Hepatocellular Carcinoma in Patients with Hepatitis C. *Ann. Intern. Med.* **2003**, *139*, 46–50. [CrossRef] [PubMed]

17. Taft, R.J.; Pang, K.C.; Mercer, T.R.; Dinger, M.; Mattick, J.S. Non-coding RNAs: Regulators of disease. *J. Pathol.* **2009**, *203*, 122–136. [CrossRef] [PubMed]

18. Iyer, M.K.; Niknafs, Y.S.; Malik, R.; Singhal, U.; Sahu, A.; Hosono, Y.; Barrette, T.R.; Prensner, J.R.; Evans, J.R.; Zhao, S.; et al. The landscape of long noncoding RNAs in the human transcriptome. *Nat. Genet.* **2015**, *47*, 199–208. [CrossRef] [PubMed]

19. Distefano, J.K. Long noncoding RNAs in the initiation, progression, and metastasis of hepatocellular carcinoma. *Non-coding RNA Res.* **2017**, *2*, 129–136. [CrossRef]

20. Marchese, F.P.; Grossi, E.; Marin-Béjar, O.; Bharti, S.K.; Raimondi, I.; González, J.; Martinez-Herrera, D.J.; Athie, A.; Amadoz, A.; Brosh, R.M.; et al. A Long Noncoding RNA Regulates Sister Chromatid Cohesion. *Mol. Cell* **2018**, *76*, 397–407. [CrossRef]

21. I Brannan, C.; Dees, E.C.; Ingram, R.S.; Tilghman, S.M. The product of the H19 gene may function as an RNA. *Mol. Cell. Biol.* **1990**, *10*, 28–36. [CrossRef] [PubMed]

22. Huang, Z.; Zhou, J.-K.; Peng, Y.; He, W.; Huang, C. The role of long noncoding RNAs in hepatocellular carcinoma. *Mol. Cancer* **2020**, *19*, 1–18. [CrossRef]

23. Yang, Y.; Chen, L.; Gu, J.; Zhang, H.; Yuan, J.; Lian, Q.; Lv, G.; Wang, S.; Wu, Y.; Yang, Y.-C.T.; et al. Recurrently deregulated IncRNAs in hepatocellular carcinoma. *Nat. Commun.* **2017**, *8*, 14421. [CrossRef] [PubMed]

24. Liu, W.-T.; Lu, X.; Tang, G.-H.; Ren, J.-J.; Liao, W.-J.; Ge, P.-L.; Huang, J.-F. LncRNAs expression signatures of hepatocellular carcinoma revealed by microarray. *World J. Gastroenterol.* **2014**, *20*, 6314–6321. [CrossRef] [PubMed]

25. Chen, Z.-Z.; Huang, L.; Wu, Y.-H.; Zhai, W.-J.; Zhu, P.-P.; Gao, Y.-F. LncSox4 promotes the self-renewal of liver tumour-initiating cells through Stat3-mediated Sox4 expression. *Nat. Commun.* **2016**, *7*, 12598. [CrossRef]

26. Fu, X.; Zhu, X.; Qin, F.; Zhang, Y.; Lin, J.; Ding, Y.; Yang, Z.; Shang, Y.; Wang, L.; Zhang, Q.-X.; et al. Linc00210 drives Wnt/β-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner. *Mol. Cancer* **2018**, *17*, 1–14. [CrossRef]

27. Huang, G.; Jiang, H.; He, Y.; Lin, Y.; Xia, W.; Luo, Y.; Liang, M.; Shi, B.; Zhou, X.; Jian, Z. LncMAPK6 drives MAPK6 expression and liver TIC self-renewal. *J. Exp. Clin. Cancer Res.* **2018**, *37*, 1–11. [CrossRef]

28. Jing, W.; Gao, S.; Zhu, M.; Luo, P.; Jing, X.; Chai, H.; Tu, J. Potential diagnostic value of IncRNA SPRY4-IT1 in hepatocellular carcinoma. *OncoL Rep.* **2016**, *36*, 1085–1092. [CrossRef] [PubMed]

29. Tong-Xin, Y.; Wang, X.-W.; Zhou, X.-L.; Liu, Z.-H.; Yang, T.-X.; Shi, W.-H.; Xie, H.-W.; Lv, J.; Wu, Q.-Q.; Cao, X.-F. Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma. *Mol. Cancer* **2015**, *14*, 1–13. [CrossRef]

30. Parnitz, K.; Tschernatsch, M.M.; Guelly, C.; Moustafa, T.; Stradner, M.; Strohmaier, H.M.; Buck, C.R.; Denk, H.; Schroeder, R.; Trauner, M.; et al. Characterization of HULC, a Novel Gene With Striking Up-Regulation in Hepatocellular Carcinoma, as Noncoding RNA. *Gastroenterology* **2007**, *133*, 330–342. [CrossRef] [PubMed]

31. Xiong, H.; Li, B.; He, J.; Zeng, Y.; Zhang, H.; Ye, F. IncRNA HULC promotes the growth of hepatocellular carcinoma cells via stabilizing COX-2 protein. *Biochem. Biophys. Res. Commun.* **2017**, *480*, 692–699. [CrossRef] [PubMed]

32. Li, S.-P.; Xu, H.-X.; Yu, Y.; He, J.-D.; Wang, Z.; Xu, Y.-J.; Wang, C.-Y.; Zhang, H.-M.; Zhang, R.-X.; Zhang, J.-J.; et al. LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. *Onco-target* **2016**, *7*, 42431–42446. [CrossRef] [PubMed]

33. Xiong, H.; Ni, Z.; He, J.; Jiang, S.; Li, X.; Gong, W.; Zheng, L.; Chen, S.; Li, B.; Zhang, N.; et al. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. *Oncogene* **2017**, *36*, 3528–3540. [CrossRef] [PubMed]
34. Chen, X.; Lin, J.; Liu, Y.; Peng, J.; Cao, Y.; Su, Z.; Wang, T.; Cheng, J.; Hu, D. AlncRNA HULC as an effective biomarker for surveillance of the outcome of cancer: A meta-analysis. *PloS ONE* **2017**, *12*, e0171210. [CrossRef] [PubMed]

35. Chen, X.; Lun, L.; Hou, H.; Tian, R.; Zhang, H.; Zhang, Y. The Value of IncRNA HULC as a Prognostic Factor for Survival of Cancer Outcome: A Meta-Analysis. *Cell. Physiol. Biochem.* **2017**, *41*, 1424–1434. [CrossRef] [PubMed]

36. Ding, Y.; Sun, C.; Li, J.; Hu, L.; Li, M.; Liu, J.; Fu, L.; Xiong, S. The Significance of Long Non-coding RNA HULC in Predicting Prognosis and Metastasis of Cancers: A Meta-Analysis. *Pathol. Oncol. Res.* **2017**, *25*, 311–318. [CrossRef]

37. Fan, Y.-H.; Wu, M.-J.; Jiang, Y.; Ye, M.; Lu, S.-G.; Wu, L.; Zhu, X.-G. Long non-coding RNA HULC as a potential prognostic biomarker in human cancers: A meta-analysis. *Onco target* **2017**, *8*, 21410–21417. [CrossRef]

38. Yang, Z.; Lu, Y.; Xu, Q.; Tang, B.; Park, C.-K.; Chen, X. HULC and H19 Played Different Roles in Overall and Disease-Free Survival from Hepatocellular Carcinoma after Curative Hepatectomy: A Preliminary Analysis from Gene Expression Omnibus. *Dis. Markers* **2015**, *2015*, 1–9. [CrossRef]

39. Li, J.; Wang, X.; Tang, J.; Jiang, R.; Zhang, W.; Ji, J.; Sun, B. HULC and Linc00152 Act as Novel Biomarkers in Predicting Diagnosis of Hepatocellular Carcinoma. *Cell. Physiol. Biochem.* **2015**, *37*, 687–696. [CrossRef] [PubMed]

40. Xie, H.; Ma, H.; Zhou, D. Plasma HULC as a Promising Novel Biomarker for the Detection of Hepatocellular Carcinoma. *BioMed Res. Int.* **2013**, *2013*, 1–5. [CrossRef]

41. Huang, J.; Zheng, Y.; Xiao, X.; Liu, C.; Lin, J.; Zheng, S.; Yang, B.; Ou, Q. A Circulating Long Noncoding RNA Panel Serves as a Diagnostic Marker for Hepatocellular Carcinoma. *Dis. Markers* **2020**, *2020*, 1–12. [CrossRef]

42. Yuan, W.; Sun, Y.; Liu, L.; Zhou, B.; Wang, S.; Gu, D. Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma. *Cell. Physiol. Biochem.* **2017**, *44*, 125–132. [CrossRef]

43. Ghafouri-Fard, S.; Esmaeili, M.; Taheri, M.; Samsami, M. Highly upregulated in liver cancer (HULC): An update on its role in carcinogenesis. *J. Cell. Physiol.* **2020**, *235*, 9071–9079. [CrossRef] [PubMed]

44. Konishi, H.; Ichikawa, D.; Yamamoto, Y.; Arita, T.; Shoda, K.; Hiramoto, H.; Hamada, J.; Itoh, H.; Fujita, Y.; Komatsu, S.; et al. Plasma level of metastasis-associated lung adenocarcinoma transcript 1 is associated with liver damage and predicts development of hepatocellular carcinoma. *Cancer Sci.* **2016**, *107*, 149–154. [CrossRef] [PubMed]

45. Tang, J.; Jiang, R.; Deng, L.; Zhang, X.; Wang, K.; Sun, B. Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma. *Onco target* **2015**, *6*, 4505–4515. [CrossRef] [PubMed]

46. Tang, J.; Zuo, H.; Zhang, X.; Jiang, R.; Ji, J.; Deng, L.; Qian, X.; Zhang, F.; Sun, B. A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma. *Cell Death Dis.* **2014**, *5*, e1549. [CrossRef]

47. El-Tawdi, A.H.F.; Matboli, M.; El-Nakeep, S.; Azazy, A.E.M.; Abdel-Rahman, O. Association of long noncoding RNA and c-JUN expression in hepatocellular carcinoma. *BioMed Res. Int.* **2018**, *2018*, 90. [CrossRef] [PubMed]

48. Zheng, Z.-K.; Pang, C.; Yang, Y.; Duan, Q.; Zhang, J.; Liu, W.-C. Serum long noncoding RNA urothelial carcinoma-associated 1: A diagnostic marker for liver cancer. *J. Cancer* **2019**, *10*, 235–245. [CrossRef]

49. El-Tawdi, A.H.F.; Matboli, M.; Shehata, H.H.; Tash, F.; El-Khazragy, N.; Azazy, A.E.-S.M.; Abdel-Rahman, O. Evaluation of Circulatory RNA-Based Biomarker Panel for Hepatocellular Carcinoma. *Mol. Diagn. Ther.* **2016**, *20*, 265–277. [CrossRef]

50. Ma, W.; Wang, H.; Jing, W.; Zhou, F.; Chang, L.; Hong, Z.; Liu, H.; Liu, Z.; Yuan, Y. Downregulation of long non-coding RNAs JPX and XIST is associated with the prognosis of hepatocellular carcinoma. *Mol. Diagn. Ther.* **2018**, *3*, 665–677. [CrossRef] [PubMed]

51. Habieb, A.; Matboli, M.; El-Tayeb, H.; El-Asmar, F. Potential role of IncRNA-TSIX, miR-548-a-3p, and SOGA1 mRNA in the diagnosis of hepatocellular carcinoma. *Mol. Biol. Rep.* **2019**, *46*, 4581–4590. [CrossRef]

52. Sun, L.; Su, Y.; Liu, X.; Xu, M.; Chen, X.; Zhu, Y.; Guo, Z.; Bai, T.; Dong, L.; Wei, C.; et al. Serum and exosome long non coding RNAs as potential biomarkers for hepatocellular carcinoma. *J. Cancer* **2018**, *9*, 2631–2639. [CrossRef]

53. Gao, S.; Xu, X.; Wang, Y.; Zhang, W.; Wang, X. Diagnostic utility of plasma IncRNA small nuclear RNA host gene 1 in patients with hepatocellular carcinoma. *Mol. Med. Rep.* **2018**, *18*, 3305–3313. [CrossRef]

54. Lu, J.; Xie, F.; Geng, L.; Shen, W.; Sui, C.; Yang, J. Investigation of serum IncRNA-ucl003wbd and IncRNA-AF085935 expression profile in patients with hepatocellular carcinoma and HBV. *Tumor Biol.* **2014**, *36*, 3231–3236. [CrossRef]

55. El-Tawdi, A.H.F.; Matboli, M.; Shehata, H.H.; Tash, F.; El-Khazragy, N.; Azazy, A.E.-S.M.; Abdel-Rahman, O. Evaluation of Circulatory RNA-Based Biomarker Panel for Hepatocellular Carcinoma. *Mol. Diagn. Ther.* **2016**, *20*, 265–277. [CrossRef]

56. Wang, K.; Guo, W.X.; Li, N.; Gao, C.F.; Shi, J.; Tang, Y.F.; Shen, F.; Wu, M.C.; Liu, S.R.; Cheng, S.Q. Serum LncRNAs Profiles Serve as Novel Potential Biomarkers for the Diagnosis of HBV-Positive Hepatocellular Carcinoma. *PLoS ONE* **2015**, *10*, e0144934. [CrossRef] [PubMed]

57. Lei, B.; Zhou, J.; Xuan, X.; Tian, Z.; Zhang, M.; Gao, W.; Lin, Y.; Ni, B.; Pang, H.; Fan, W. Circular RNA expression profiles of peripheral blood mononuclear cells in hepatocellular carcinoma patients by sequence analysis. *Cancer Med.* **2019**, *8*, 1423–1433. [CrossRef] [PubMed]
59. Zhang, X.; Xu, Y.; Qian, Z.; Zheng, W.; Wu, Q.; Chen, Y.; Zhu, G.; Liu, Y.; Bian, Z.; Xu, W.; et al. circRNA_104075 stimulates YAP-dependent tumorigenesis through the regulation of HNF4a and may serve as a diagnostic marker in hepatocellular carcinoma. *Cell Death Dis.* 2018, 9, 1–14. [CrossRef]

60. Wang, W.; Li, Y.; Li, X.; Liu, B.; Han, S.; Li, X.; Zhang, B.; Li, J.; Sun, S. Circular RNA circ-FOX1 induced by SOX9 promotes hepatocellular carcinoma progression via sponging miR-875-3p and miR-421. *Biomed. Pharmacother.* 2020, 121, 105917. [CrossRef]

61. Li, Z.; Zhou, Y.; Yang, G.; He, S.; Qu, X.; Zhang, L.; Deng, Q.; Zheng, F. Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma. *Clin. Chim. Acta* 2019, 492, 37–44. [CrossRef]

62. Qiao, G.-L.; Chen, L.; Jiang, W.-H.; Yang, C.; Yang, C.-M.; Song, L.-N.; Chen, Y.; Yan, H.-L.; Ma, L.-J. Hsa_circ_0003998 may be used as a new biomarker for the diagnosis and prognosis of hepatocellular carcinoma. *OncoTargets Ther.* 2019, 12, 5849–5860. [CrossRef]

63. Zhu, K.; Zhan, H.; Peng, Y.; Yang, L.; Gao, Q.; Jia, H.; Dai, Z.; Tang, Z.; Fan, J.; Zhou, J. Plasma hsa_circ_0027089 is a diagnostic biomarker for hepatitis B virus-related hepatocellular carcinoma. *Carcinogenesis* 2020, 41, 296–302. [CrossRef] [PubMed]

64. Chen, W.; Quan, Y.; Fan, S.; Wang, H.; Liang, J.; Huang, L.; Chen, L.; Liu, Q.; He, P.; Ye, Y. Exosome-transmitted circular RNA hsa_circ_0051443 suppresses hepatocellular carcinoma progression. *Cancer Lett.* 2020, 475, 119–128. [CrossRef] [PubMed]

65. Sun, X.-H.; Wang, Y.-T.; Li, G.-F.; Zhang, N.; Fan, L. Serum-derived three-circRNA signature as a diagnostic biomarker for hepatocellular carcinoma. *Cancer Cell Int.* 2020, 20, 1–8. [CrossRef] [PubMed]

66. Wu, C.; Deng, L.; Zhuo, H.; Chen, X.; Tan, Z.; Han, S.; Tang, J.; Qian, X.; Yao, A. Circulating circRNA predicting the occurrence of hepatocellular carcinoma in patients with HBV infection. *J. Cell. Mol. Med.* 2020, 24, 10216–10222. [CrossRef] [PubMed]

67. Xiong, D.; Sheng, Y.; Ding, S.; Chen, J.; Fan, L.; Zeng, T.; Qin, D.; Zhu, L.; Huang, A.; Tang, H. LINC00052 regulates the expression of NTRK3 by miR-128 and miR-485-3p to strengthen HCC cells invasion and migration. *Oncoargets* 2016, 7, 47593–47608. [CrossRef]

68. Ji, J.; Tang, J.; Deng, L.; Xie, Y.; Jiang, R.; Li, G.; Sun, B. LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway. *Oncoargets* 2015, 6, 42813–42824. [CrossRef]

69. Neumann, O.; Kesselmeier, M.; Geffers, R.; Pellegrino, R.; Radl, A.; Hoffmann, K.; Ehemann, V.; Schemmer, P.; Schirmacher, P.; Bermejo, J.L.; et al. Methylation analysis and integrative profiling of human HCCs identify novel protumorigenic factors. *Hepatology* 2012, 56, 1817–1827. [CrossRef]

70. Lijun, Q.; Shao, Y.; Zhang, X.; Zheng, T.; Miao, M.; Qin, L.; Liu, B.; Han, S.; Li, J.; Sun, S. Circular RNA circ-FOXP1 induced by SOX9 promotes hepatocellular carcinoma progression through miR-216b and activation of FGFR1/ERK signaling. *Pathol. Res. Pr.* 2019, 1260–1272. [CrossRef]

71. Wang, F.; Li, X.; Xie, X.; Zhao, L.; Chen, W. UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling. *Minerva Med.* 2017, 108, 119–128. [CrossRef] [PubMed]

72. Duan, W.; Du, L.; Jiang, X.; Wang, R.; Yan, S.; Xie, Y.; Yan, K.; Wang, Q.; Wang, L.; Zhang, X.; et al. Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer. *Oncoargets* 2016, 7, 78850–78858. [CrossRef] [PubMed]

73. Pan, J.; Xie, X.; Li, H.; Li, Z.; Ren, C.; Ming, L. Detection of serum long non-coding RNA UCA1 and circular RNAs for the diagnosis of bladder cancer and prediction of recurrence. *Int. J. Clin. Exp. Pathol.* 2019, 12, 2951–2958. [PubMed]

74. Wang, J.; Gao, Y.; Wang, X.; Gao, Y.; Li, L.; Zhang, J.; Zhang, L.; Che, F. Circulating IncRNAs as noninvasive biomarkers in bladder cancer: A diagnostic meta-analysis based on 15 published articles. *Int. J. Biol. Markers* 2020, 35, 40–48. [CrossRef] [PubMed]

75. Wang, W.; Yin, Z. Diagnostic Value of Long Non-Coding RNA H19, UCA1, and HOTAIR as Promising Biomarkers in Human HCCs: A Systematic Review of Literature. *Cancer Lett.* 2017, 39, 11659–11665. [CrossRef]

76. Li, J.; Gao, J.; Kan, A.; Hao, T.; Huang, L. SNHG and UCA1 as prognostic molecular biomarkers in hepatocellular carcinoma: Recent research and meta-analysis. *Minerva Med.* 2017, 108, 568–574. [PubMed]

77. Wang, F.; Yang, H.-Q.; He, B.-S.; Pan, Y.-Q.; Deng, Q.-W.; Sun, H.-L.; Chen, J.; Liu, X.; Wang, S.-K. Upregulated IncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. *Oncoargets* 2015, 6, 7899–7917. [CrossRef]

78. Qin, L.-T.; Tang, R.-X.; Lin, P.; Li, Q.; Yang, H.; Luo, D.-Z.; Chen, G.; He, Y.; Li, P. Biological function of UCA1 in hepatocellular carcinoma and its clinical significance: Investigation with in vitro and meta-analysis. *Pathol. Res. Pr.* 2018, 214, 1260–1272. [CrossRef]

79. Luo, J.-H.; Ren, B.; Keryanov, S.; Tseng, G.C.; Rao, U.N.M.; Monga, S.P.; Strom, S.; Demetris, A.J.; Nalesnik, M.; Yu, Y.P.; et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. *Hepatology* 2006, 44, 1012–1024. [CrossRef]

80. Lai Zhong, M.-C.; Yang, Z.; Zhou, L.; Zhu, Q.-Q.; Xie, H.-Y.; Zhang, F.; Wu, L.-M.; Chen, L.-M.; Zheng, S. Long non-coding RNA MALAT1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. *Med Oncol.* 2012, 29, 1810–1816. [CrossRef]

81. Hou, Z.; Xu, X.; Zhou, L.; Fu, X.; Tao, S.; Zhou, J.; Tan, D.; Liu, S. The long non-coding RNA MALAT1 promotes the migration and invasion of hepatocellular carcinoma by sponging miR-204 and releasing SIRT1. *Tumor Biol.* 2017, 39, 1010428317718135. [CrossRef]

82. Mei, H.; Liu, Y.; Zhou, Q.; Hu, K.; Liu, Y. Long noncoding RNA MALAT1 acts as a potential biomarker in cancer diagnosis and detection: A meta-analysis. *Biomark. Med.* 2019, 13, 45–54. [CrossRef]
110. Yu, J.; Han, J.; Zhang, J.; Li, G.; Liu, H.; Cui, X.; Xu, Y.; Li, T.; Liu, J.; Wang, C. The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis. *Medicine* 2016, 95, e4436. [CrossRef]

111. Zhang, H.-G.; Grizzle, W.E. Exosomes. *Am. J. Pathol.* 2014, 184, 28–41. [CrossRef] [PubMed]

112. Mathivanan, S.; Ji, H.; Simpson, R.J. Exosomes: Extracellular organelles important in intercellular communication. *J. Proteom.* 2010, 73, 1907–1920. [CrossRef]

113. Kim, K.M.; Abdelmohsen, K.; Mustacic, M.; Kapogiannis, D.; Gorospe, M. RNA in extracellular vesicles. *Wiley Interdiscip. Rev. RNA* 2017, 8, e1413. [CrossRef]

114. Dragomir, M.; Chen, B.; Calin, G.A. Exosomal lncRNAs as new players in cell-to-cell communication. *Transl. Cancer Res.* 2018, 7, S524–S525. [CrossRef]

115. Li, Y.; Zheng, Q.; Bao, C.; Li, S.; Guo, W.; Zhao, J.; Chen, D.; Gu, J.; He, X.; Huang, S. Circular RNA is enriched and stable in exosomes: A promising biomarker for cancer diagnosis. *Cell Res.* 2015, 25, 981–984. [CrossRef]

116. Huang, X.; Sun, L.; Wen, S.; Deng, D.; Wan, F.; He, X.; Tian, L.; Liang, L.; Wei, C.; Gao, K.; et al. RNA sequencing of plasma exosomes revealed novel functional long non-coding RNAs in hepatocellular carcinoma. *Cancer Sci.* 2020, 111, 3338–3349. [CrossRef]

117. Lu, Y.; Duan, Y.; Xu, Q.; Zhang, L.; Chen, W.; Qu, Z.; Wu, B.; Liu, W.; Shi, L.; Wu, D.; et al. Circulating exosome-derived bona fide long non-coding RNAs predicting the occurrence and metastasis of hepatocellular carcinoma. *J. Cell. Mol. Med.* 2019, 24, 1311–1318. [CrossRef]

118. Cao, S.-Q.; Zheng, H.; Sun, B.-C.; Wang, Z.-L.; Liu, T.; Guo, D.-H.; Shen, Z.-Y. Long non-coding RNA highly up-regulated in liver cancer promotes exosome secretion. *World J. Gastroenterol.* 2019, 25, 5283–5299. [CrossRef]

119. Xu, L.-C.; Chen, Q.-N.; Liu, X.-Q.; Wang, X.-M.; Chang, Q.-M.; Pan, Q.; Wang, L.; Wang, Y. Up-regulation of LINC00161 correlates with tumor migration and invasion and poor prognosis of patients with hepatocellular carcinoma. *Oncotarget* 2017, 8, 56168–56173. [CrossRef]

120. Matboli, M.; Labib, M.E.; El-Tayeb, H.; El-Tawdi, A.H.; Habib, E.K.; Ali-Labib, R. Exosomal miR-1298 and IncRNA-RP11-583F2.2 Expression in Hepatocellular Carcinoma. *Curr. Genom.* 2020, 21, 46–55. [CrossRef]

121. Ali, H.S.; Boshra, M.S.; El Meteini, M.S.; Matboli, M.; Matboli, M. IncRNA- RP11-156p1.3, novel diagnostic and therapeutic targeting via CRISPR/Cas9 editing in hepatocellular carcinoma. *Genomics* 2020, 112, 3306–3314. [CrossRef] [PubMed]

122. Zhang, C.; Yang, X.; Qi, Q.; Gao, Y.; Wei, Q.; Han, S. IncRNA HEIH in serum and exosomes as a potential biomarker in the HCV-related hepatocellular carcinoma. *Cancer Biomark.* 2018, 21, 651–659. [CrossRef] [PubMed]

123. Ma, Y.; Cao, D.; Li, G.; Hu, J.; Liu, X.; Liu, J. Silence of lncRNA HEIH suppressed liver cancer cell growth and metastasis through miR-199a-3p/mTOR axis. *J. Cell. Biochem.* 2019, 120, 17757–17766. [CrossRef] [PubMed]

124. Wu, M.-M.; Shen, W.-D.; Zou, C.-W.; Chen, H.-J.; Guo, H.-M. LncRNA HEIH Suppresses Hepatocellular Carcinoma Cell Growth and Metastasis by up-Regulating MiR-199a-3p. *Eur. Rev. Med. Pharmacol. Sci.* 2020, 24, 6031–6038. [CrossRef]

125. Shen, Q.; Jiang, S.; Wu, M.; Zhang, L.; Su, X.; Zhao, D. LncRNA HEIH Confers Cell Sorafenib Resistance in Hepatocellular Carcinoma by Regulating miR-98-5p/PI3K/AKT Pathway. *Cancer Manag. Res.* 2020, 12, 6585–6595. [CrossRef]

126. Nieminen, A.I.; Eskelinen, V.M.; Haikala, H.M.; Tervonen, T.A.; Yan, Y.; Partanen, J.I.; Klefström, J. Myc-induced AMPK-phosphorylation of KIF15 Expression in Tumor-associated Monocytes Is a Prognostic Biomarker in Hepatocellular Carcinoma. *Sci. Rep.* 2016, 6, 39296. [CrossRef] [PubMed]

127. Lopez-Soto, A.; Gonzalez, S.; Smyth, M.J.; Galluzzi, L. Control of Metastasis by NK Cells. *PLoS ONE* 2015, 10, e0230905. [CrossRef] [PubMed]

128. Lu, Y.; Cui, X.; Liao, X.; Li, S.; Wang, L.; Wang, J.; Wang, Y.-F.; Zhang, Y.; Zhou, X.; Zhou, Y. PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment. *Cancer Genom. Proteom.* 2018, 15, 3306–3314. [CrossRef] [PubMed]

129. Wang, X.; Chen, Q.; Zhao, L.; Zhang, H.; Pan, Q.; Wang, W.; Wang, Y. Identification of human peripheral blood monocyte gene markers for early screening of solid tumors. *Cell Stress* 2018, 2, 295–309. [CrossRef]

130. Zheng, Y.; Li, Y.; Lian, J.; Yang, H.; Li, F.; Zhao, S.; Qi, Y.; Zhang, Y.; Huang, L. TNF-α-Induced TIM-3 Expression Markers of Tumor Infiltrating Natural Killer Cells in Human Esophageal Cancer. *J. Transl. Med.* 2019, 17, 1–12. [CrossRef]

131. Ringelhan, M.; Pfister, D.; O’Connor, T.; Pikarsky, E.; Heikenwalder, M. The immunology of hepatocellular carcinoma. *Nat. Immunol.* 2018, 19, 222–232. [CrossRef]

132. Chen, S.; Liu, M.; Liang, B.; Ge, S.; Peng, J.; Huang, H.; Xu, Y.; Tang, X.; Deng, L. Identification of human peripheral blood monocyte gene markers for early screening of solid tumors. *PLoS ONE* 2015, 20, e0230905. [CrossRef] [PubMed]

133. Iwata, T.; Kondo, Y.; Kimura, O.; Morosawa, T.; Fujisaka, Y.; Umeda, K.; Togure, T.; Inoue, J.; Nakagome, Y.; Shimosegawa, T. PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment. *Sci. Rep.* 2016, 6, 39296. [CrossRef] [PubMed]

134. Kitagawa, A.; Masuda, T.; Takahashi, J.; Tobo, T.; Noda, M.; Kuroda, Y.; Hu, Q.; Kouyama, Y.; Kobayashi, Y.; Kuramitsu, S.; et al. KIF15 Expression in Tumor-associated Monocytes Is a Prognostic Biomarker in Hepatocellular Carcinoma. *Cancer Genom. Proteom.* 2020, 17, 141–149. [CrossRef] [PubMed]

135. Brown, C.J.; Lafreniere, R.G.; Powers, V.E.; Sebastio, G.; Ballabio, A.; Pettigrew, A.L.; Ledbetter, D.H.; Levy, E.; Craig, I.W.; Willard, H.F. Localization of the X inactivation centre on the human X chromosome in Xq13. *Nat. Cell Biol.* 1991, 349, 82–84. [CrossRef] [PubMed]

136. Lee, J.T.; Davidow, L.S.; Warshawsky, D. Tsix, a gene antisense to Xist at the X-inactivation centre. *Nat. Genet.* 1999, 21, 400–404. [CrossRef] [PubMed]
137. Lin, X.-Q.; Huang, Z.-M.; Chen, X.; Wu, F.; Wu, W. XIST Induced by JPX Suppresses Hepatocellular Carcinoma by Sponging miR-155-5p. Yonsei Med J. 2018, 59, 816–826. [CrossRef]

138. Ishibashi, M.; Kogo, R.; Shibata, K.; Sawada, G.; Takahashi, Y.; Kurashige, J.; Akiyoshi, S.; Sasaki, S.; Iwaya, T.; Sudo, T.; et al. Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma. Oncol. Rep. 2012, 29, 946–950. [CrossRef]

139. Gao, J.-Z.; Li, J.; Du, J.-L.; Li, X.-L. Long non-coding RNA HOTAIR is a marker for hepatocellular carcinoma progression and tumor recurrence. Oncol. Lett. 2016, 11, 1791–1798. [CrossRef] [PubMed]

140. Fujisaka, Y.; Iwata, T.; Tamai, K.; Nakamura, M.; Mochizuki, M.; Shibuya, R.; Yamaguchi, K.; Shimosegawa, T.; Satoh, K. Long non-coding RNA HOTAIR up-regulates chemokine (C-C motif) ligand 2 and promotes proliferation of macrophages and myeloid-derived suppressor cells in hepatocellular carcinoma cell lines. Oncol. Lett. 2017, 15, 509–514. [CrossRef]